Amneal Celebrates FDA Approvals For Generic Namzaric And Afinitor Disperz

Amneal builds on its affordable medicines business with three FDA approvals – two final and one tentative – for generic rivals referencing AbbVie’s Namzaric, Novartis’ Afinitor Disperz, and Bausch Health’s Xifaxan.